tiprankstipranks
Trending News
More News >
TOT BIOPHARM International Co. Ltd. (HK:1875)
:1875
Hong Kong Market
Advertisement

TOT BIOPHARM International Co. Ltd. (1875) AI Stock Analysis

Compare
0 Followers

Top Page

HK:1875

TOT BIOPHARM International Co. Ltd.

(1875)

Rating:71Outperform
Price Target:
HK$3.00
▲(20.00% Upside)
The overall stock score reflects strong financial recovery and favorable technical indicators, showing positive market momentum. However, the high valuation and liquidity concerns from negative Free Cash Flow present potential risks. The absence of dividend yield also limits its appeal for income investors.

TOT BIOPHARM International Co. Ltd. (1875) vs. iShares MSCI Hong Kong ETF (EWH)

TOT BIOPHARM International Co. Ltd. Business Overview & Revenue Model

Company DescriptionTOT BIOPHARM International Co. Ltd. (1875) is a leading biopharmaceutical company based in China, specializing in the research, development, manufacturing, and commercialization of oncology drugs and therapies. The company's core focus is on innovative biologics and biosimilars aimed at treating various forms of cancer. With a commitment to improving patient outcomes, TOT BIOPHARM leverages advanced technologies and strategic partnerships to deliver high-quality, affordable treatments.
How the Company Makes MoneyTOT BIOPHARM generates revenue primarily through the sale of its oncology drugs and therapies. The company invests in the development of both proprietary biologics and biosimilars, which are critical in the treatment of cancer. Revenue streams include direct sales to healthcare providers and distributors, as well as potential licensing agreements and partnerships with other pharmaceutical companies for co-development and commercialization. Additionally, the company might receive government grants or subsidies that support its research and development efforts. Key factors contributing to its earnings include its robust pipeline of drug candidates, strategic collaborations, and its ability to bring cost-effective treatments to market.

TOT BIOPHARM International Co. Ltd. Financial Statement Overview

Summary
The company has shown significant improvement in revenue, profitability, and operational efficiency, with positive EBIT and EBITDA margins. The balance sheet is strong with low Debt-to-Equity Ratio and positive Return on Equity. However, liquidity remains a concern due to negative Free Cash Flow.
Income Statement
75
Positive
The company has shown a significant improvement in revenue and profitability. Gross Profit Margin and Net Profit Margin have improved substantially from negative to positive, indicating a turnaround. The EBIT and EBITDA margins have moved from negative to positive, highlighting improved operational efficiency. However, the company faced challenges in previous years with negative growth, which could indicate potential volatility.
Balance Sheet
80
Positive
The balance sheet is strong with a relatively low Debt-to-Equity Ratio, indicating prudent financial leverage. The Return on Equity has turned positive, suggesting effective use of shareholder funds. The Equity Ratio is stable, showing a solid equity base. The company has maintained a healthy cash position over the years, enhancing financial stability.
Cash Flow
60
Neutral
The cash flow statements show some concerns. The Free Cash Flow remains negative, impacting the cash flow score. However, the company has improved its Operating Cash Flow to Net Income Ratio, reflecting better cash generation from operations. Continued negative Free Cash Flow indicates potential liquidity challenges, although the company has managed its financing activities to maintain cash reserves.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue1.10B780.63M442.18M76.33M22.49M
Gross Profit782.43M573.99M370.62M27.47M15.53M
EBITDA84.96M10.45M-5.41M-224.51M-254.71M
Net Income34.76M-37.76M-49.92M-261.22M-288.50M
Balance Sheet
Total Assets1.51B1.43B1.26B710.26M641.18M
Cash, Cash Equivalents and Short-Term Investments381.26M358.36M458.05M152.81M225.53M
Total Debt395.47M345.65M289.53M208.56M7.41M
Total Liabilities779.12M739.41M546.59M375.17M58.83M
Stockholders Equity729.65M686.69M713.88M335.09M582.36M
Cash Flow
Free Cash Flow-7.17M-146.77M-180.19M-290.45M-285.30M
Operating Cash Flow116.40M56.43M59.93M-175.14M-263.12M
Investing Cash Flow-122.50M-164.10M-282.76M-108.39M12.53M
Financing Cash Flow34.18M38.23M481.24M212.08M-61.71M

TOT BIOPHARM International Co. Ltd. Technical Analysis

Technical Analysis Sentiment
Positive
Last Price2.50
Price Trends
50DMA
2.03
Positive
100DMA
1.96
Positive
200DMA
1.89
Positive
Market Momentum
MACD
0.17
Negative
RSI
62.95
Neutral
STOCH
53.30
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1875, the sentiment is Positive. The current price of 2.5 is above the 20-day moving average (MA) of 2.19, above the 50-day MA of 2.03, and above the 200-day MA of 1.89, indicating a bullish trend. The MACD of 0.17 indicates Negative momentum. The RSI at 62.95 is Neutral, neither overbought nor oversold. The STOCH value of 53.30 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:1875.

TOT BIOPHARM International Co. Ltd. Peers Comparison

Overall Rating
UnderperformOutperform
Sector (60)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
71
Outperform
HK$1.92B48.164.92%38.48%
60
Neutral
HK$17.54B4.97-4.95%3.61%9.71%-38.85%
57
Neutral
HK$1.97B-12.04%260.78%40.04%
48
Neutral
HK$2.19B-86.56%190.48%40.11%
37
Underperform
HK$2.16B-228.99%44.88%
36
Underperform
HK$1.90B-67.57%54.79%
32
Underperform
HK$1.74B-12.49%50.94%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
HK:1875
TOT BIOPHARM International Co. Ltd.
2.49
0.54
27.69%
HK:6978
Immunotech Biopharm Ltd
4.08
1.13
38.31%
HK:6622
Zhaoke Ophthalmology Ltd.
3.60
2.26
168.66%
HK:2181
Mabpharm Limited
0.52
0.16
44.44%
HK:2185
Shanghai Bio-Heart Biological Technology Co., Ltd. Class H
4.04
2.59
178.62%
HK:2511
Hightide Therapeutics Inc
3.17
1.39
78.09%

TOT BIOPHARM International Co. Ltd. Corporate Events

BioDlink International Schedules Board Meeting for Interim Results
Jul 31, 2025

BioDlink International Company Limited has announced that its board of directors will convene on August 12, 2025, to review and approve the interim financial results for the first half of the year ending June 30, 2025. This meeting is crucial for stakeholders as it will provide insights into the company’s financial health and operational performance, potentially impacting its market positioning and investor confidence.

The most recent analyst rating on (HK:1875) stock is a Buy with a HK$3.00 price target. To see the full list of analyst forecasts on TOT BIOPHARM International Co. Ltd. stock, see the HK:1875 Stock Forecast page.

BioDlink International Rebrands with New Name and Identity
Jul 25, 2025

BioDlink International Company Limited has officially changed its English name from TOT BIOPHARM International Company Limited, effective July 11, 2025, following shareholder approval. This change is accompanied by amendments to the Articles of Association, a new stock short name ‘BIODLINK-B’ effective July 30, 2025, a new website address, and a new company logo, reflecting the company’s rebranding efforts.

The most recent analyst rating on (HK:1875) stock is a Buy with a HK$3.00 price target. To see the full list of analyst forecasts on TOT BIOPHARM International Co. Ltd. stock, see the HK:1875 Stock Forecast page.

TOT BIOPHARM Updates Nomination Committee Terms to Enhance Governance
Jun 30, 2025

TOT BIOPHARM International Co. Ltd. has announced the approval and implementation of new Terms of Reference for its Nomination Committee, effective July 1, 2025. The committee is tasked with reviewing the board’s structure, identifying qualified director candidates, and ensuring board diversity and independence. This move is expected to enhance the company’s governance and align its board composition with its strategic goals, potentially impacting its market positioning and stakeholder confidence.

The most recent analyst rating on (HK:1875) stock is a Buy with a HK$3.00 price target. To see the full list of analyst forecasts on TOT BIOPHARM International Co. Ltd. stock, see the HK:1875 Stock Forecast page.

TOT BIOPHARM Passes Key Resolutions at AGM
Jun 20, 2025

TOT BIOPHARM International Co. Ltd. successfully passed all proposed resolutions at its Annual General Meeting held on June 20, 2025. These resolutions included the approval of financial statements, re-election of directors, and granting of mandates for share allotment and buyback, indicating strong shareholder support and strategic alignment for future corporate governance and operational strategies.

The most recent analyst rating on (HK:1875) stock is a Buy with a HK$3.00 price target. To see the full list of analyst forecasts on TOT BIOPHARM International Co. Ltd. stock, see the HK:1875 Stock Forecast page.

TOT BIOPHARM Announces 2025 AGM Details and Key Resolutions
May 28, 2025

TOT BIOPHARM International Co. Ltd. has announced the details of its upcoming annual general meeting, scheduled for June 20, 2025. The meeting will address several key resolutions, including the approval of the company’s financial statements for 2024, the re-election of board members, and the reappointment of PricewaterhouseCoopers as auditors. Additionally, the meeting will consider authorizing the board to manage the company’s share capital, which could impact the company’s financial strategy and shareholder value.

The most recent analyst rating on (HK:1875) stock is a Buy with a HK$3.00 price target. To see the full list of analyst forecasts on TOT BIOPHARM International Co. Ltd. stock, see the HK:1875 Stock Forecast page.

TOT BIOPHARM Proposes Name Change to BioDlink International
May 28, 2025

TOT BIOPHARM International Co. Ltd. has announced a proposal to change its English name to BioDlink International Company Limited, subject to shareholder and regulatory approval. This name change is intended to better align with the company’s business strategy and enhance its corporate image, without affecting current shareholders’ rights or the company’s operations.

The most recent analyst rating on (HK:1875) stock is a Buy with a HK$3.00 price target. To see the full list of analyst forecasts on TOT BIOPHARM International Co. Ltd. stock, see the HK:1875 Stock Forecast page.

TOT BIOPHARM Reports Revenue Growth Amidst Profitability Challenges in Q1 2025
May 12, 2025

TOT BIOPHARM International Co. Ltd. reported a 13% year-on-year increase in revenue for the first quarter of 2025, reaching RMB252,200 thousand. This growth is primarily due to the steady increase in sales of its self-developed products. Despite the revenue growth, the company’s net income decreased compared to the same period last year, highlighting potential challenges in maintaining profitability. Stakeholders are advised to exercise caution as the company’s financial results have shown fluctuations in the past and may continue to do so.

The most recent analyst rating on (HK:1875) stock is a Buy with a HK$3.0000 price target. To see the full list of analyst forecasts on TOT BIOPHARM International Co. Ltd. stock, see the HK:1875 Stock Forecast page.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 30, 2025